

Pharmacotherapy of patients with benign prostate enlargement and storage symptoms in everyday clinical practice

R. ZDROJOWY¹, A.J. OWCZAREK², M. OLSZANECKA-GLINIANOWICZ³,
A. ALMGREN-RACHTAN⁴, J. CHUDEK⁵

¹Department of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland

²Department of Statistics, Department of Instrumental Analysis, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland

³Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland

⁴Department of Pharmacovigilance, Europharma Rachtan Co. Ltd., Katowice, Poland

⁵Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland

Abstract. – OBJECTIVE: Storage symptoms significantly deteriorate the quality of life in men with benign prostate enlargement (BPE). Muscarinic receptor antagonists (MRAs) and β 3-adrenergic receptors agonists alone, or in combination with selective α 1-alpha-antagonists, are considered the most effective medicines relieving storage symptoms. The aim of this study was to analyze the pharmacotherapy of storage symptoms in men with BPE, and their compliance with the European Association of Urology (EAU) guidelines.

PATIENTS AND METHODS: The survey was conducted in 2018 by 261 urologists among 24,613 men with lower urinary tract symptoms (LUTS) and BPE treated pharmacologically. Data concerning recent severity of non-neurological LUTS, storage symptoms and pharmacotherapy were collected.

RESULTS: Storage symptoms were reported by 12,356 patients (50.2%) with BPE, more frequently nocturia (75.8%), than urinary urgency (57.8%) and frequency (44.3%). Patients with storage symptoms were more frequently prescribed with MRAs and mirabegron (43.1% vs. 5.0% and 2.4% vs. 0.3%, respectively; $p < 0.001$). Of note, 54.5% of patients with storage symptoms were treated neither with MRAs, nor β 3-adrenergic receptors agonists. In the subgroup with storage symptoms, the increasing severity of LUTS accounted for more frequent prescription of MRA (2.1% vs. 29.1% vs. 42.8% in patients with mild, moderate, and severe LUTS, respectively). Decision tree analysis revealed that patients with urinary urgency and urinary frequency, as well as younger ones with urinary urgency but without urinary frequency, were more frequently prescribed with MRAs.

CONCLUSIONS: Urinary urgency and frequency are associated with increased utilization of MRAs in men with BPE in everyday clinical practice. The attitude of Polish urologists toward management of persistent storage symptoms in BPE patients is in line with the EAU guidelines.

Key Words:

Lower urinary tract symptoms, Benign prostate enlargement pharmacotherapy, Real-life data, Everyday clinical practice, Muscarinic receptor antagonists, Storage symptoms, Urinary urgency, Urinary incontinence.

Introduction

Extension of the lifetime in developed countries results in the increasing prevalence of benign prostatic hyperplasia (BPH) and the related, so called, non-neurogenic lower urinary tract symptoms (LUTS)¹. Progressive benign prostate enlargement (BPE) impairs the outflow of urine from the bladder and leads to an entity that is known as bladder outlet obstruction (BOO). The outflow disturbances are followed by hypertrophy and overactivity of the detrusor muscle². BOO impairs both emptying and storage of urine in the bladder, that are manifested by weakness of the urine stream, incomplete emptying, frequent urination, urgency, and nocturia. The symptoms, to a various extent, deteriorate the quality of life, related to occurrence of sleep disorders, anxiety,

embarrassment associated with the disease, reduced mobility, as well as impairment of sexual activity and satisfaction with sexual relations³⁻⁶.

In 2000, the European Association of Urology (EAU) developed guidelines on the management of non-neurogenic male LUTS, that were subsequently updated⁷. According to the guidelines from 2017, pharmacotherapy in BPH should not be offered to men with mild/moderate LUTS, minimally bothered by their symptoms (watchful waiting). The therapy (monotherapy with selective α 1-alpha-antagonists – ARAs) should be initiated in those with moderate-to-severe symptoms. ARAs are effective in reducing LUTS and increasing the peak urinary flow rate, but neither reduce prostate volume, nor prevent acute urinary retention (AUR). While 5- α reductase inhibitors (5 α RI) should be offered in monotherapy, or in combination with ARAs, to men with moderate-to-severe symptoms and an increased risk of disease progression (prostate volume > 40 mL), these drugs increase the peak urinary flow rate, decrease prostate volume and the risk of AUR, as well as the need for surgery, however, may reduce libido, deteriorate potency and cause ejaculation disorders. In addition, the guidelines recommend the use of muscarinic receptor antagonists (MRAs) in men with bladder storage symptoms not associated with increased void residual volume (> 150 mL). These drugs can significantly improve urgency, urinary incontinence, and increased daytime frequency. As an alternative to MRAs, the guidelines recommend the use of β ₃-adrenoceptors agonist (mirabegron).

Pharmacotherapy for non-neurogenic LUTS should be individualized taking into account not only the severity and structure but also the dominance of certain symptoms, as well as prostate volume, co-morbidities and patient expectations and preferences. In patients with mostly storage LUTS, the first-line treatment should be lifestyle advice and behavioral modifications (restriction of caffeine, alcohol and fluid intake at the evening, weight reduction in the overweight and obese, training of bladder control strategies)⁸. If not effective, MRAs and β ₃-adrenoceptors agonists, alone or in combination with ARAs⁹⁻¹¹ are considered as more effective than other pharmacological strategies. While in men with concomitant voiding LUTS in the course of BPH, ARAs and 5 α RI allow for the improvement in the storage symptoms¹².

A survey performed among Polish urologists, shortly after the publication of the 2013 edition

of EAU guidelines, showed that 10% urologists start pharmacotherapy in patients with minimal-to-moderate LUTS. ARAs were the first line treatment option both for patients with (48.8% urologists) and without (84.8% urologists) BPE while only 17.1% urologists were choosing 5 α RI in monotherapy, and 29.6% prescribed them with ARAs as the primary treatment. MRAs were an acceptable treatment option for storage LUTS in the opinion of 83.7% of urologists¹³. This survey assessed the urologists' declarations concerning therapy but did not verify their everyday prescription practice.

The aim of this study was to analyze the pharmacotherapy of storage symptoms in men with BPE, and their compliance with the guidelines.

Patients and Methods

This large cohort study was carried out in 2018 by 231 urologists and 30 under-training residents, on a group of 37,165 outpatients (men) with LUTS, pharmacologically treated for at least two weeks. Patients' agreement to participate in the survey was the only additional inclusion criteria for eligible outpatients. Inability to obtain answers to questions in the questionnaire was the only exclusion criterion. The survey did not meet the criterion of a medical experiment and did not require an approval of the Bioethical Committee. The study organizer (Europharma Rachtan Co. Ltd., Katowice, Poland) processed only anonymized patients' data.

Survey Procedures

Urologists were recruited among doctors working in urological outpatient clinics, effectively collaborating in the previous projects. The survey was supported by a study questionnaire, that was filled out by the investigator participating in the survey based on an interview and data from the medical history during a single visit resulting from clinical needs. Data of eligible patients that refused to participate were not collected.

The individual patients' questionnaires included data concerning: age, educational level, place of residence, clinical data (period of time since the diagnosis of BPH, the occurrence of enlarged prostate volume (> 30 mL in transabdominal sonography), storage symptoms (nocturia, urinary frequency, urinary urgency, and urge incontinence), recent severity of LUTS according to the International Prostate Symptom Score (I-PSS)

reported as mild (0-7 pts), moderate (8-19 pts) and severe (20-35 pts)¹⁴, current pharmacotherapy for BPH, and main factors that affected the choice of drugs.

The survey was combined with patients' education concerning methods of involuntary urination management if needed.

Statistical Analysis

There were 37,165 questionnaires completed by the investigators. Patients records without prostate enlargement (< 30 ml in transabdominal sonography examination) and those with missing data were excluded (N = 12,552). Statistical analysis was performed using the STATISTICA 13.0 PL software (Tibco Software Inc, Palo Alto, CA, USA), StataSE 12.0 (StataCorp LLC, Collage Station, TX, USA). Statistical significance was set at a *p*-value below 0.05. All tests were two-tailed. No data imputation was performed. Nominal and ordinal data were expressed as percentages, while interval data were expressed as mean value ± standard deviation. Distribution of variables was evaluated by the Shapiro-Wilk test and the Cullen-Frey graph. Homogeneity of variances was assessed by the Fisher-Snedecor test. For comparison of data, the one-way ANOVA analysis was used with RIR Tukey posthoc test. Categorical variables were compared using χ^2 tests. Classification and regression trees were built with Gini index as a measure of goodness of fit, equal classification error and 10-times cross validation.

Results

Study Group Characteristics

The analysis included 24,613 of 37,165 men prescribed with medication for BPH at the mean age of 69 ± 8 yrs., currently reporting mild (23.1%), moderate (67.5%) or severe (9.4%) LUTS. Storage symptoms were reported by 12,356 patients (50.2%), most frequently nocturia – 75.8%, then urinary urgency (usually without urine incontinence) – 57.8%, and urinary frequency – 44.3%. Patients with storage symptoms were characterized by higher prevalence of men with severe LUTS and those with over 5 years history of treatment for BPH (Table I).

BPH Pharmacotherapy

In the entire study group, the most commonly used pharmacotherapy was ARAs in monother-

apy – 36.6%, or in a combination therapy with 5 α RI – 30.9%. MRAs were prescribed either with ARAs – 11.2%, or on top of ARA+5 α RI therapy – 30.9%. Mirabegron, the only selective β_3 -adrenoceptors agonist available in Poland, was used in 1.4% of men only (Table I).

Patients with storage symptoms were more frequently prescribed with MRA containing pharmacotherapy and/or mirabegron (43.1% vs. 5.0%; *p* < 0.001; and 2.4% vs. 0.3%; *p* < 0.001; respectively). Of note, 54.5% of patients with storage symptoms were not treated with MRAs and/or β_3 -adrenergic receptors agonists.

In the subgroup of patients with storage symptoms, the increasing severity of LUTS accounted for more frequent prescription of MRA-based pharmacotherapy (from 2.1% in patients with mild, through 29.1% with moderate, to 42.8% with severe LUTS). In patients with moderate LUTS, MRAs were used with similar frequency as ARAs and as ARA+5 α RI; while in individuals with severe LUTS much more frequently on top of ARA+5 α RI therapy (Table II).

Tamsulosin was the most commonly used ARA (70.1%), while doxazosin (20.0%) and alfuzosin (6.2%) came as second and third. With the increasing severity of LUTS, the prescription of doxazosin with ARAs was increasing (from 16.9 to 24.4%, *p* < 0.001), while the prescription of alfuzosin was decreasing (from 5.8 to 3.3%; *p* < 0.001). The occurrence of urinary urgency was associated with more frequent use of doxazosin (14.0 vs. 22.4%; *p* < 0.001) but less frequent use of tamsulosin (75.1 vs. 68.0%; *p* < 0.001) and alfuzosin (7.5 vs. 5.7%; *p* < 0.001). The data concerning the use of specific 5 α RI was not collected, as finasteride is the almost exclusively 5 α RI used in Poland.

Of the available MRAs, tolterodine (20.2%) and solifenacin (9.0%) were most commonly used; while oxybutynin (1.4%), and darifenacin (0.1%) were used much less frequently.

Decision Trees

Patients with moderate/severe severity of LUTS, older and with higher educational level (73.1%) were more likely to be prescribed with 5 α RI (Figure 1).

Similarly, patients with urinary urgency with urinary frequency (72.4% of them) as well as younger ones with urinary urgency but without urinary frequency (74.8% of them) were more likely to receive prescription for MRAs (Figure 2).

Table I. The characteristics of the analysed group of men with prostatic enlargement, pharmacologically treated for BPH.

	Whole group [N = 24,613]	Storage symptoms		p
		Yes [N = 12,356]	No [N = 12,257]	
Age [years]	69 ± 8	70 ± 9	68 ± 8	< 0.001
Age ≥ 65 yrs. [N; %]	17,404; 70.7	9,281; 75.1	8,123; 66.3	< 0.001
Education level [N; %]				
Primary	2,391; 9.7	1,314; 10.6	1,077; 8.8	< 0.001
Vocational	6,499; 26.4	4,165; 33.7	2,334; 19.0	
Secondary	11,192; 45.5	4,637; 37.5	6,555; 53.5	
Higher	4,531; 18.4	2,240; 18.1	2,291; 18.7	
Place of residence [N; %]				
Rural	4,667; 19.0	2,764; 22.4	1,903; 15.5	< 0.001
Small city (< 50 ths. inhabitants)	5,666; 23.0	2,665; 21.6	3,001; 24.5	
Large city (≥ 50 ths. inhabitants)	14,280; 58.0	6,927; 56.0	7,353; 60.0	
Period of time since the diagnosis of BPH [N; %]				
≤ 5 yrs.	16,407; 66.7	7,805; 63.2	8,602; 70.2	< 0.001
> 5 yrs.	8,206; 33.3	4,551; 36.8	3,655; 29.8	
Severity of LUTS [N; %]				
0-7 pts – mild	5,681; 23.1	986; 8.0	4,695; 38.3	< 0.001
8-19 pts – moderate	16,608; 67.5	9,495; 76.8	7,113; 58.0	
20-35 pts – sever	2,324; 9.4	1,875; 15.2	449; 3.7	
Storage symptoms				
Urinary urgency [N; %]	7,139; 29.0	7,139; 57.8	-	-
without incontinence	6,359; 25.8	6,359; 51.5	-	-
with incontinence	780; 3.2	780; 6.3	-	-
Nocturia [N; %]	9,369; 38.1	9,369; 75.8	-	-
Urinary frequency [N; %]	5,470; 22.2	5,470; 44.3	-	-
Medication for BPH [N; %]				
Phytotherapy	263; 1.1	195; 1.6	68; 0.6	< 0.001
ARA	8,997; 36.6	2,093; 16.9	6,904; 56.3	< 0.001
5αRI	1,477; 6.0	662; 5.4	815; 6.7	< 0.001
ARA + MRA	2,749; 11.2	2,356; 19.1	393; 3.2	< 0.001
ARA + 5αRI	7,596; 30.9	3,781; 30.6	3,815; 31.1	< 0.001
ARA + 5αRI + MRA	3,191; 13.0	2,965; 24.0	226; 1.8	< 0.001
ARA + 5αRI + MIR	323; 1.3	288; 2.3	35; 0.3	< 0.001
ARA + 5αRI + MRA + MIR	17; 0.1	16; 0.1	1; 0.01	-

ARA – selective α1-alpha-adrenolytic; 5αRI – 5-alpha reductase inhibitor; MIR – mirabegron; MRA – muscarinic receptor antagonist.

Discussion

Our real-life data concerning current pharmacotherapy for benign prostate enlargement (BPE) shows that ARAs monotherapy remains as the most frequent therapeutic option utilized in more than one-third of patients. It is in line with the survey performed among Polish urologists, showing that ARAs in monotherapy was the first line option for patients with and even without BPE¹³. When comparing the prescribed medication for non-neurogenic LUTS with the data coming from the PolSenior study¹⁵, performed in years 2007-2012, one may see that the prescription of ARAs in monotherapy has declined from 64.7 to 25.6% during last years,

possibly as a consequence of later guidelines from 2010. In parallel, during this period of time, there was an increase in the utilization of ARA+5αRI combined therapy from 21.9% to 30.9% and most spectacularly the use of MRAs (in the combined therapy) from 1.7 to 23.6%. The increase in the utilization of MRAs, revealed by our observation, is in line with the treatment option accepted by 83.7% of Polish urologists concerning MRAs' use for the management of storage LUTS¹³, while the most recently introduced drug – mirabegron is currently rarely used (1.4% of overall study population and 2.4% of those with storage symptoms), probably due to the lack of reimbursement from Polish National Health Fund. Of note, 54.5% of patients

Table II. Comparison of patients with prostatic enlargement and storage symptoms in respect to the severity of LUTS.

	Severity of LUTS			p
	≤ 7 pts. [N=5,681]	8-19 pts. [N=16,608]	≥ 20 pts. [N=2,324]	
Age [years]	68 ± 8	69 ± 8	72 ± 7	< 0.001
Age ≥ 65 yrs. [N; %]	3,794; 66.8	11,602; 69.9	2,008; 86.4	< 0.001
Period of time since the diagnosis of BPH [N; %]				
≤ 5 yrs.	3,913; 68.9	11,549; 69.5	945; 40.7	< 0.001
> 5 yrs.	1,768; 31.1	5,059; 30.5	1,379; 59.3	
Urinary urgency [N; %]	189; 3.3	5,775; 34.8	1,175; 50.6	< 0.001
Without incontinence	189; 3.3	5,055; 30.4	1,115; 48.0	0.001
With incontinence	0	720; 4.3	60; 2.6	
Nocturia [N; %]	887; 15.6	6,765; 40.7	1,717; 73.9	< 0.001
Urinary frequency [N; %]	135; 2.4	4,452; 26.8	883; 38.0	< 0.001
Medication for BPH [N; %]				
Phytotherapy	74; 1.3	189; 1.1	0	< 0.001
ARA	4,270; 75.2	4,570; 27.5	157; 6.8	< 0.001
5αRI	182; 3.2	1167; 7.0	128; 5.5	< 0.001
ARA + MRA	91; 1.6	2,410; 14.5	248; 10.7	< 0.001
ARA + 5αRI	364; 14.4	3,118; 31.5	858; 43.8	< 0.001
ARA + 5αRI + MRA	31; 0.6	2,414; 14.6	746; 32.1	< 0.001
ARA + 5αRI + MIR	144; 2.5	176; 1.1	3; 0.1	< 0.001
ARA + 5αRI + MRA + MIR	0	16; 0.1	1; 0.04	< 0.001

ARA – selective α1-alpha-adrenolytic; 5αRI – 5-alpha reductase inhibitor; MIR – mirabegron; MRA – muscarinic receptor antagonist.

with storage symptoms were treated neither with MRAs nor with β₃-adrenergic receptors agonists, despite the EAU recommendations.

Similarly to Poland, the ARAs monotherapy is the most frequently utilized medication for BOO in the USA, yet slowly decreasing during the last decade from 74.6% in 2006 to 68.7% in 2014 in favor of monotherapy with 5αRI¹⁶. BOO medication in the USA was characterized by more profound underutilization of MRAs than in Poland (based on our data). Only 3.7% of the USA cohort

with BPH/LUTS were prescribed with MRAs (5.7% of those receiving other BOO medication) with no significant increase in the study period (2006-2014).

A different landscape is presented by a recent MERCURE study from Spain¹⁷, that analyzed the compliance with the EAU 2013 recommendations in the management of LUTS in men. In this study, treatment with ARAs in monotherapy and ARAs with MRAs was almost equally frequent (37.5 vs. 37.2%, respectively).




Figure 1. Decision tree for the use of 5αRI - 5-alpha reductase inhibitor in the study group. Accuracy of this decision tree was 70.1%.




Figure 2. Decision tree for the use of MRA - muscarinic receptor antagonist in the study group. Accuracy of this decision tree was 83.5%.

Having in mind the recommended individualization of pharmacotherapy for non-neurogenic LUTS, that take into account not only the severity, prostate volume, structure/dominance of certain symptoms, but also co-morbidities as well as patients' expectations and preferences, we analyzed how storage symptoms (urinary urgency, frequency and nocturia) affects the prescription of 5 α RI and MRAs. We have demonstrated that decisions concerning pharmacotherapy with MRAs was affected mostly by the occurrence of urinary urgency and urinary frequency, but not nocturia, among the storage symptoms. In addition, MRAs were more frequently prescribed in younger adults (< 65 years old). While the decision concerning the use of 5 α RI was mostly affected by severity of LUTS, older age and education level.

The more frequent choice of 5 α RI in older men is potentially explainable by a benefit from reducing the risk of prostate cancer during long-term treatment with these drugs¹⁸, while bearing the risk of decrease in libido, ejaculation disorders and painful enlargement of the breast¹⁹. However, it is hard to say whether it reflects patients' preferences or the knowledge of the physicians.

The relatively high costs of MRAs therapy in Poland probably explains the more frequent use of these drugs in triple, rather than double schedule, and more prevalent utilization of cheaper tolterodine rather than solifenacin (in 20.2 and 9.0% of MRAs users, respectively). The low utilization of mirabegron (more expensive than MRAs), the only currently available β_3 -adrenoceptors agonist, in patients with storage symptoms is in line with this statement. Our data indirectly demonstrates how per capita income modifies the application of the EAU recommendations in European societies²⁰.

Study limitations are related to the methodology. The survey was focused mostly of the current clinical presentation of storage symptoms, and not those preceding the initiation of pharmacotherapy. The survey did not collect the data concerning the changes in medication during the therapy. We cannot exclude some overrepresentation of patients with more severe symptoms, potentially, more frequently utilizing medical services. The generalization of the data is restricted to Polish population due to the effect of drug reimbursement policy by the national health system. Furthermore, the study demonstrates the situation before the COVID-19 pandemic. The recommendations by urological societies during ongoing

pandemic prioritization of pharmacotherapy and postponing of elective surgery for BPH²¹, might change utilization of pharmacotherapy for benign prostate enlargement.

Conclusions

Urinary urgency and frequency are associated with increased utilization of MRAs in men with BPE in everyday clinical practice. The attitude of Polish urologists toward management of persistent storage symptoms in BPE patients is in line with EAU guidelines.

Conflict of Interest

The Authors declare that they have no conflict of interests.

ORCID ID

Romuald Zdrojowy, ORCID: 0000-0002-1634-3556. Aleksander Jerzy Owczarek, ORCID: 0000-0003-1179-6932. Magdalena Olszanecka-Glinianowicz, ORCID: 0000-0001-5632-5590. Jerzy Chudek, ORCID: 0000-0002-6367-7794.

Funding Acknowledgement

This study was funded by a scientific grant of Recordati Polska Co. Ltd. (RECO/BPH1/2018). Europharma Rachtan Co. Ltd. designed the study and is the copyright holder.

Authors' Contribution

Concept and study design M. Olszanecka-Glinianowicz & A. Almgren-Rachtan; data analysis A.J. Owczarek, J. Chudek; manuscript preparation R. Zdrojowy, J. Chudek. Consultations: Prof. Andrzej Prajsner – retired Head and Chair of the Department of Urology, Medical University of Silesia in Katowice.

Ethical Statement

According to the Polish law, surveys are not medical experiments and as such do not require either Bioethical Committee approval or the need to obtain informed consent from the patients for inclusion.

Disclosure

Romuald Zdrojowy received a consultation fee for the manuscript editing. Aleksander Jerzy Owczarek received honorarium for statistical analysis. Magdalena Olszanecka-Glinianowicz received honorarium for the project drafting. Agnieszka Almgren-Rachtan is employed by Europharma Rachtan Co. Ltd (Director of the Department of Pharmacovigilance). Jerzy Chudek received honorarium for data analysis and manuscript drafting.

References

- 1) Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. *J Urol* 1984; 132: 474-479.
- 2) Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurourol Urodynam* 2002; 21: 167-178.
- 3) Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, McKinlay JB. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. *Arch Intern Med* 2006; 166: 2381-2387.
- 4) Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. *Eur Urol* 1997; 31: 272-280.
- 5) Emberton M, Martorana G. BPH: social impact and patient's perspective. *Eur Urol Suppl* 2006; 5: 991-996.
- 6) Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. *BJU Int* 2005; 95: 15-19.
- 7) Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, Rieken M, Speakman MJ, Tikkinen KAO. Management of Non-neurogenic Male LUTS. Available at: <https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts>.
- 8) Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Cullkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. *J Urol* 2012; 188 (6 Suppl): 2455-2463.
- 9) Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. *JAMA* 2006; 296: 2319-2328.
- 10) Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. *J Urol* 2009; 182: 2825-2830.
- 11) Matsuo T, Miyata Y, Kakoki K, Yuzuriha M, Asai A, Ohba K, Sakai H. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α 1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. *BMC Urol* 2016; 16: 45.
- 12) Gacci M, Sebastianelli A, Spatafora P, Corona G, Serni S, De Ridder D, Gravas S, Abrams P. Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. *Ther Adv Urol* 2017; 10: 79-92.
- 13) Borkowski T, Golabek T, Chlosta PL, Borkowski A. Evaluation and management of male lower urinary tract symptoms: treatment patterns and guidelines in a correlation study among Polish urology consultants. *Arch Med Sci* 2015; 11: 1340-1351.
- 14) Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. *J Urol* 1992; 148: 1549-1557.
- 15) Praitsner A, Chudek J, Szybalska A, Piotrowicz K, Zejda J, Więcek A. Socioeconomic profile of elderly Polish men treated for benign prostate hyperplasia: results of the population-based PolSenior study. *Eur Geriatr Med* 2015; 6: 53-57.
- 16) Vouri SM, Strobe SA, Olsen MA, Xian H, Schootman M. Antimuscarinic use in men treated with bladder outlet obstruction medication therapy. *Urology* 2018; 122: 76-82.
- 17) Errando-Smet C, Müller-Arteaga C, Hernández M, Roset M. Diagnosis and treatment of male patients with lower urinary tract symptoms in Spain – The MERCURY Study. Do urologists follow the recommendations of the European guidelines? *Actas Urol Esp* 2018; 42: 323-330.
- 18) Azzouni F, Mohler J. Role of 5 α -reductase inhibitors in prostate cancer prevention and treatment. *Urology* 2012; 79: 1197-1205.
- 19) Azzouni F, Mohler J. Role of 5 α -reductase inhibitors in benign prostatic diseases. *Prostate Cancer Prostatic Dis* 2012; 15: 222-230.
- 20) Barlik M, Jacyków D, Lewandowska B, Mirosław J, Siwiak K, Wągrowka U. Household budget survey in 2018. Statistics Poland. <https://stat.gov.pl/obszary-tematyczne/warunki-zycia/dochody-wydatki-i-warunki-zycia-ludnosci/budzety-gospodarstw-domowych-w-2018-r-,9,13.html> (published Sept 27, 2019).
- 21) Amparore D, Campi R, Checcucci E, Sessa F, Pecoraro A, Minervini A, Fiori C, Ficarra V, Novara G, Serni S, Porpiglia F. Forecasting the future of urology practice: a comprehensive review of the recommendations by International and European Associations on Priority Procedures During the COVID-19 Pandemic. *Eur Urol Focus* 2020; 6: 1032-1048.